Research Headline: Liquid Biopsy Results Explained

Why one phrase covers five different tests

"Liquid biopsy" sounds like a single thing. It is not. The phrase describes any test that looks for signs of cancer in a blood sample rather than in a piece of tissue, and it gets used for at least five separate jobs:

• Screening: looking for cancer in someone with no symptoms and no diagnosis.
• Diagnosis: helping confirm cancer when tissue is hard to obtain.
• Biomarker selection: finding a specific mutation to decide which drug to use.
• Minimal residual disease: checking for traces left after treatment.
• Monitoring: watching for the cancer changing or returning over time.

Those five uses have wildly different evidence behind them. A headline that does not say which one it means has told you very little.

What is being measured

Cells shed DNA as they die, and that DNA circulates in the bloodstream. Fragments from a tumor are called circulating tumor DNA, usually shortened to ctDNA.

The technical difficulty is proportion. Tumor DNA may be a very small fraction of the total DNA floating in a blood sample, so the test has to detect a faint signal against a loud background. How small that fraction is depends on the tumor's size, its type, and where it sits — which is why these tests perform very differently from one situation to another.

The asymmetry at the heart of it

A positive liquid biopsy result is usually informative. A negative one often is not.

This is not a caveat invented by cautious editors. It is written into FDA approvals. The 2016 premarket approval for the first plasma-based EGFR test states directly that patients who test negative on a plasma sample should be sent for a routine tissue biopsy and tested again on tissue.

The reason is simple: some tumors do not shed enough DNA into the blood to be detected. A negative result may mean the mutation is absent, or it may mean the test could not see it.

So the practical rule is that a positive result can act on its own, while a negative one usually needs tissue to confirm. Our page on measurable disease covers a related distinction in how disease is assessed.

The question that decides the meaning

Before a result means anything, you need to know why the test was ordered.

For choosing a drug, the test is doing well-established work. NCI describes biomarker testing as looking for genes, proteins, and other substances that give information about a cancer, and notes that some targeted therapies and immunotherapies only work in cancers carrying particular biomarkers. A companion diagnostic is a biomarker test formally paired with a specific treatment.

For minimal residual disease, the test is looking for traces of cancer after treatment that scans cannot see. This is an active research area, and a positive result does not automatically mean treatment should change. Our explainer on what MRD means covers the terminology.

For screening healthy people, the evidence bar is far higher and largely still being established. A test that works well for choosing a drug in someone with known cancer is not thereby a screening test.

Two errors to keep in view

False positives. In screening especially, testing many people with no cancer means some abnormal results will not reflect cancer at all. Each one leads to more scans, more anxiety, and sometimes procedures with their own risks.

False negatives. As above, a clear blood result does not clear the person. It particularly does not override symptoms.

Neither error is a flaw unique to liquid biopsy. Every test has them. What matters is knowing which one is more likely in the situation you are in.

Symptoms still outrank a normal blood test

This is the point most likely to matter to someone reading a headline. A reassuring test result does not cancel a symptom that will not go away.

Book an appointment, regardless of any recent test, for:

• Bleeding without an obvious cause: in stool or urine, when coughing, between periods, or after menopause.
• A lump that is new, firm, or growing, or that has lasted beyond three weeks.
• Unexplained weight loss over 10% of your body weight in six months.
• A cough, hoarseness, or difficulty swallowing lasting more than three weeks.
• A change in bowel habit lasting more than three weeks.
• Persistent pain with no explanation, or pain that does not settle as expected.

Questions patients can ask

• Was this test ordered for screening, for choosing a drug, for checking residual disease, or for monitoring?
• What would a positive result change, and what would a negative one change?
• Is tissue testing still needed either way?
• What are the chances of a false positive or false negative in my specific situation?
• Is this standard care, or is it a research test? Our page on trials versus standard treatment covers that difference.

What this story cannot tell

• It cannot tell whether a headline applies to any particular person with cancer.
• It cannot replace a treatment plan from a care team.
• It cannot establish that one option is best for everyone.
• It cannot support starting, stopping, or changing treatment without medical advice.
• It cannot resolve the difference between a test that is available and a test that is proven for a given purpose.

Sources

• National Cancer Institute, Biomarker Testing for Cancer Treatment: https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment
• U.S. Food and Drug Administration, Premarket Approval P150047, cobas EGFR Mutation Test v2: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150047

How this page was made

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

See an error, old source, or unclear wording? Tell us.